Senolytic Therapy to Modulate Progression of Alzheimer's Disease

1. Age 65 years or above.

2. Clinical diagnosis of AD (MoCA 10-20 and Clinical Dementia Rating Scale/CDR = 1) on a stable dose of cholinesterase inhibitors for at least three months

3. Body Mass Index (BMI) within range of 19 - 35 kg/ m2

4. Labs: Normal blood cell counts without clinically significant excursions (WBCs: 4,500-10,500 cells/mcL; absolute neutrophil count: 1,800-8,700 cells/mcL; platelets: 140-450 K/uL; hemoglobin 12.0-17.5 grams/dL); liver and renal function (AST 10-40 IU/L, total bilirubin 0.1-1.4 mg/dl); cholesterol (<240 mg/dl), triglycerides (<300 mg/dl), and glucose control (HbA1c < 7%). PT/PTT/INR within normal limits

5. Participants must be accompanied by a Legally Authorized Representative designated to sign informed consent and to provide study partner reported outcomes at all remaining visits

6. Participants must have no plans to travel over the next 4-5 months that interfere with study visits following consent

1. Hearing, vision, or motor deficits despite corrective devices;

2. Alcohol or drug abuse;

3. MRI contraindications;

4. Myocardial infarction, angina, stroke or transient ischemic attack in the past 6 months; QT interval >440 on ECG will not be enrolled. Chronic heart failure will be exclusionary;

5. Participants with coagulation disorders;

6. Neurologic, musculoskeletal, or other condition that limits subject's ability to complete study physical assessments;

7. Uncontrolled diabetes (HbA1c > 7% or the current use of insulin);

8. Current or chronic history of liver disease, or known hepatic or biliary abnormalities;

9. Use of anti-arrhythmic medications known to cause QTc prolongation, anti-platelet or anti-coagulant medication;

10. Current use of quinolone antibiotics.

11. Poorly controlled blood pressure (systolic BP>160, diastolic BP>90 mmHg).

12. Active inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignant, and psychiatric disease.

13. History of or MRI-positive for any space occupying lesion, including mass effect or abnormal intracranial pressure, which would indicate contraindication to lumbar puncture